Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22690713 | 1.00 | MDM4 (0.44) | MDM4TP53SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL22690715 | 1.00 | MDM4 (0.44) | MDM4TP53SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL31476468 | 0.85 | KMT2A (0.42) | MDM4TP53MAPTRAB9ANPSR1 | |
| SCHEMBL29529171 | 0.85 | ITGA4 (0.50) | MDM4TP53MDM2ITGA4ITGB7 | |
| SCHEMBL31520512 | 0.85 | CYP1A2 (0.43) | ALDH1A1MAPTRAB9ANPSR1HTR2A | |
| SCHEMBL14600028 | 0.84 | MGLL (0.40) | MDM2HTR2A | |
| SCHEMBL5557405 | 0.84 | MGLL (0.40) | MDM2HTR2A | |
| SCHEMBL31520518 | 0.84 | HTR2A (0.43) | MDM4TP53ALDH1A1MAPTRAB9A | |
| SCHEMBL22960724 | 0.84 | MDM4 (0.43) | MDM4TP53ALDH1A1MDM2 | |
| SCHEMBL31520535 | 0.82 | HTR2A (0.42) | ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |